RareCyte

14 articles about RareCyte

• RareCyte® Inc. reports significant 2021 growth of Precision Biology™ Services business and customer uptake of Orion™ Spatial Biology instruments and reagents

  1/6/2022

  RareCyte Inc., ("RareCyte" or "The Company") a leading provider of Precision Biology products and services recognized over 100% sales growth in their Services business in 2021.

• RareCyte® Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels

  9/9/2021

  RareCyte, Inc. a Life Sciences company developing and manufacturing proprietary platforms enabling precision biology solutions, announced the completion of a $24M financing from new and existing investors.

• RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer

  8/26/2020

   RareCyte ® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer. The ARv

• RareCyte® announces the Orion™ spatial biology platform with breakthrough technology for same-day highly multiplexed tissue analysis

  7/16/2020

  A complete platform of instrumentation, software, and reagents for rapid fluorescence staining and 21-channel whole-slide imaging

• RareCyte announces the first blood-to-result PD-L1 Circulating Tumor Cell Assay

  2/27/2020

  RareCyte announces a liquid biopsy blood test for programmed death-ligand 1, enabling customers to evaluate PD-L1 expression on circulating tumor cells with industry leading sensitivity.

• RareCyte Closes $22M Financing for Global Commercialization and Platform Expansion into Tissue Multiplexing

  12/19/2019

  RareCyte, Inc. ("RareCyte" or "the Company") a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing from new and existing investors.

• RareCyte expands liquid biopsy offering with the release of a HER2/ER breast cancer CTC Panel Kit

  10/31/2019

  RareCyte announces an addition to the RarePlex® Staining Kit product line, enabling customers to evaluate HER2 and ER expression on circulating tumor cells in their own laboratory.

• RareCyte launches prostate cancer ARv7 CTC Kit for liquid biopsy analysis

  10/30/2019

  RareCyte announces the launch of a new RarePlex® Staining Kit, enabling customers to evaluate prostate cancer specific expression of ARv7 on circulating tumor cells (CTC) in their own laboratory.

• New RarePlex Developer Kits for CTC characterization provide researchers flexibility in independent CTC assay development

  10/29/2019

  The RarePlex Staining Kit family includes Panel Kits and Developer Kits which may be used in combination to create custom assays.

• RareCyte introduces comprehensive CyteFinder II platform for fast, multiplexed imaging that enables multi-omic results for liquid biopsy and tissue analysis

  3/28/2019

  RareCyte® announces the CyteFinder® II and CyteFinder II HT Instruments in conjunction with the American Association for Cancer Research Annual Meeting in Atlanta, March 29 through April 3.

• RareCyte expands liquid biopsy offerings with the RarePlex™ CTC Developer Kit for custom biomarkers, and introduces the next generation CytePicker® Cell Retrieval Module for single cell and tissue micro-region retrieval

  3/11/2019

  RareCyte, Inc., a global rare cell detection and liquid biopsy company, announces its newest products, the RarePlex™ CTC Developer Kit, and the next generation CytePicker® Cell Retrieval Module in conjunction with the Molecular Med Tricon Meeting in San Francisco March 10 through 15.

• Seattle's RareCyte Nabs $30 Million for Commercial Expansion of Rare Cell Detection Technology for Liquid Biopsies

  8/30/2017

• RareCyte Release: Analysis Of Rare Circulating Fetal Cells Make Possible A New Type Of Noninvasive Genetic Prenatal Testing

  10/24/2016

• Frank Witney Joins RareCyte Board Of Directors

  8/18/2016